Replies to post #244438 on Biotech Values

[DewDiligence]

PRDS 4Q22 results:

https://www.globenewswire.com/news-release/2023/03/14/2627160/0/en/Pardes-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

Cash at 12/31/22 was $197M, down $12M from 9/30/22.

PRDS expects to report phase-2 data for its COVID antiviral, Pomotrelvir* in the next few weeks.

No CC.

*f/k/a PBI-451 or PBI-0451.